成纤维细胞生长因子受体3改变与转移性尿路上皮癌患者对PD-1/PD-L1阻断的应答
基于两项探索转移性尿路上皮癌检查点抑制(CPI)的临床试验数据,比较FGFR3突变型与野生型患者的应答率,未发现统计学显著差异。FGFR3突变型肿瘤突变负荷相似、T细胞浸润较低、基质/TGF-β信号也较低,作者认为FGFR3突变状态并非CPI耐药生物标志物,并为FGFR3抑制剂与CPI联合方案提供依据。
要点
- FGFR3突变型与野生型转移性尿路上皮癌对CPI的应答率无统计学显著差异。
- FGFR3突变型肿瘤突变负荷与野生型相似,T细胞浸润较低,基质/TGF-β信号也较低。
- 作者认为FGFR3突变状态不是CPI耐药生物标志物,并为联合方案提供依据。
核心结论
- FGFR3突变状态不是检查点抑制(CPI)耐药的生物标志物。
- FGFR3突变型与野生型转移性尿路上皮癌的应答率无统计学显著差异。
- FGFR3抑制剂单药与CPI单药在FGFR3突变型尿路上皮癌中均有活性且可能非交叉耐药,为联合方案提供依据。
研究设计与样本
- 基于两项探索CPI治疗转移性尿路上皮癌的临床试验数据进行分析。
主要发现
- FGFR3突变型与野生型转移性尿路上皮癌患者的应答率无统计学显著差异。
- 与FGFR3野生型相比,FGFR3突变型尿路上皮癌肿瘤突变负荷相似、T细胞浸润较低、基质/转化生长因子β(TGF-β)信号也较低。
临床怎么用
- 作者认为FGFR3突变状态不是CPI耐药的生物标志物。
- 作者提出FGFR3突变型尿路上皮癌中FGFR3抑制剂与CPI单药均有活性且可能非交叉耐药,为联合方案提供依据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior studies have demonstrated that fibroblast receptor 3 (FGFR3)-mutant urothelial cancers (UCs) are associated with decreased T-cell infiltration. As FGFR3 mutations are enriched in luminal-like UC and luminal-like UC has been shown to be relatively less responsive to PD-1/PD-L1 inhibition (checkpoint inhibition [CPI]), these data have led to the speculation that FGFR3 mutations may be causally related to poor T-cell infiltration and that UC patients harboring FGFR3 mutations may be suboptimal candidates for CPI. Using data derived from two clinical trials exploring CPI in metastatic UC, we demonstrate no statistically significant difference in response rates in patients with FGFR3-mutant versus wild-type UC. We present hypothesis-generating data, suggesting that similar response rates may be explained by a "balancing out" of previously identified independent positive and negative predictors of CPI sensitivity; that is, compared with FGFR3 wild-type UC, FGFR3-mutant UC is associated with a similar tumor mutational burden, lower T-cell infiltration, but also lower stromal/transforming growth factor beta (TGF-β) signals. Based on our findings, FGFR3 mutation status is not a biomarker of resistance to CPI. Indeed, the single-agent activity of both FGFR3 inhibitors and CPI in FGFR3-mutant UC, and potential non-cross resistance provide a strong pragmatic rationale for combination approaches. PATIENT SUMMARY: In this report, we examined the impact of a mutated gene found in a subset of urothelial cancers on response to treatment with immunotherapy. We found that patients with tumors harboring mutations in the gene FGFR3 respond to immunotherapy similarly to patients without such mutations.
引用
- Wang L, Gong Y, Saci A, et al. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019. PMID: 31272788. doi:10.1016/j.eururo.2019.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。